Abstract:Pt(IV) anticancer compounds have been developed for several decades to overcome the drawbacks of their Pt(II) congeners, and the reduction of Pt(IV) to Pt(II) has been commonly regarded as a necessary step in the activation of Pt(IV) compounds prior to targeting DNA. However, blockage of glutathione (GSH) biosynthesis resulted in a slight effect on the cytotoxicity of oxoplatin in yeast Saccharomyces cerevisiae strains, urging us to reconsider the mechanism of actions for the "inert" Pt(IV) complexes. Using X-ray absorption near-edge spectroscopy (XANES), our data demonstrated that Pt(IV) complex oxoplatin could bind to DNA in a tetravalent state. Both alkaline denaturing agarose electrophoresis and thermal denaturation-renaturation assay revealed that oxoplatin could rapidly produce stable interstrand crosslinks (ICLs), which can further translate into a fast cell-killing process in cancer cells. Using quantitative real-time PCR and immunofluorescence analysis, we also proved that Pt(IV) complex oxoplatin could induce a quick intracellular response of the FA/BRCA pathway in cancer cells that involves the DNA interstrand crosslinking repair system, and this quick response to ICLs was independent with the intracellular GSH levels. Cell cycle analysis showed that short incubation with oxoplatin can induce a strong S phase arrest in HeLa cells, indicating that the rapid interstrand crosslinks produced by oxoplatin might stall the replication fork, result in the double-strand breaks, and eventually induce cell death. Our results implied that, besides the reduction mechanism to release the Pt(II) congeners, direct and rapid interstrand cross-linking with DNA by Pt(IV) compounds might be a unique mechanism for Pt(IV) compounds, which may provide new insight for the development of next-generation platinum-based drugs.

A Pt(II) complex bearing N-heterocycle ring induced ferroptotic cell death in ovarian cancer

A Pt(II) complex bearing N-heterocycle ring induced ferroptotic cell death in ovarian cancer

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Ferroptosis: A Novel Anti-tumor Action for Cisplatin

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies

New Platinum(ii)-Based DNA Intercalator: Synthesis, Characterization and Anticancer Activity

Pt(IV) Prodrugs Containing Microtubule Inhibitors Displayed Potent Antitumor Activity and Ability to Overcome Cisplatin Resistance.

Construction Of Dual Stimuli-Responsive Platinum(Iv) Hybrids With Nqo1 Targeting Ability And Overcoming Cisplatin Resistance

Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer via a multi-mechanism

Rapid DNA interstrand cross-linking of Pt(IV) compound

A GSH-depleted Platinum（iv） Prodrug Triggers Ferroptotic Cell Death in Breast Cancer

Chiral RuII‐PtIIComplexes Inducing Telomere Dysfunction Against Cisplatin‐Resistant Cancer Cells

A mitochondria-targeting hetero-binuclear Ir(iii)-Pt(ii) complex induces necrosis in cisplatin-resistant tumor cells.

A Trifunctional Pt(II) Complex Alleviates the NHEJ/HR-related DSBs Repairs to Evade Cisplatin-Resistance in NSCLC.

Development of Cu(II) 4-Hydroxybenzoylhydrazone Complexes That Induce Mitochondrial DNA Damage and Mitochondria-Mediated Apoptosis in Liver Cancer

Mitochondrial DNA-targeting and impairment by a dinuclear Ir-Pt complex that overcomes cisplatin resistance

Ptxplatin: An multifunctional Pt(IV) antitumor prodrug

BODIPY-Appended Pt(II) Complexes with High Toxicities and Anti-chemoresistance Performances in a Cisplatin Resistant in Vivo Model.

Novel Monofunctional Platinum (Ii) Complex Mono-Pt Induces Apoptosis-Independent Autophagic Cell Death In Human Ovarian Carcinoma Cells Distinct From Cisplatin